OKYO PHARMA LTD (OKYO) Stock Price, Quote, News and Overview
NASDAQ:OKYO - Nasdaq - GG00BMFG5F62 - Common Stock - Currency: USD
OKYO Quote, Performance and Key Statistics
1.84
+0.19 (+11.52%)
The current stock price of OKYO is 1.84 USD. In the past month the price increased by 21.72%. In the past year, price increased by 39.39%.
OKYO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.77 | 322.91B | ||
| AMGN | AMGEN INC | 13.1 | 146.19B | ||
| GILD | GILEAD SCIENCES INC | 13.79 | 132.89B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.58B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.47 | 64.44B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.59B | ||
| ARGX | ARGENX SE - ADR | 99.05 | 35.50B | ||
| ONC | BEIGENE LTD-ADR | 5.93 | 25.74B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.82B | ||
| NTRA | NATERA INC | N/A | 20.73B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.14B | ||
| BIIB | BIOGEN INC | 7.98 | 18.51B |
Related stock screener links
About OKYO
Company Profile
OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The firm is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. Its research program is focused on a novel G Protein-Coupled Receptor (GPCR). The firm is developing OK-101, its lead preclinical product candidate, for the treatment of DED. OK-101 is focused on keratoconjunctivitis sicca, commonly referred to as DED, which is a multifactorial disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. The firm also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. The company is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.
Company Info
OKYO PHARMA LTD
Floor 4, 14/15 Conduit St
London GB
Employees: 8
Phone: 442074952379
OKYO PHARMA LTD / OKYO FAQ
What is the stock price of OKYO PHARMA LTD today?
The current stock price of OKYO is 1.84 USD. The price increased by 11.52% in the last trading session.
What is the ticker symbol for OKYO PHARMA LTD stock?
The exchange symbol of OKYO PHARMA LTD is OKYO and it is listed on the Nasdaq exchange.
On which exchange is OKYO stock listed?
OKYO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for OKYO PHARMA LTD stock?
7 analysts have analysed OKYO and the average price target is 7.14 USD. This implies a price increase of 288.04% is expected in the next year compared to the current price of 1.84. Check the OKYO PHARMA LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is OKYO PHARMA LTD worth?
OKYO PHARMA LTD (OKYO) has a market capitalization of 40.06M USD. This makes OKYO a Nano Cap stock.
How many employees does OKYO PHARMA LTD have?
OKYO PHARMA LTD (OKYO) currently has 8 employees.
What are the support and resistance levels for OKYO PHARMA LTD (OKYO) stock?
OKYO PHARMA LTD (OKYO) has a support level at 1.41. Check the full technical report for a detailed analysis of OKYO support and resistance levels.
Should I buy OKYO PHARMA LTD (OKYO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of OKYO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of OKYO, evaluating the profitability, health, valuation and growth aspects
- OKYO PHARMA LTD (OKYO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- OKYO PHARMA LTD (OKYO) Sales and EPS estimates to see what analysts future expectations are.
- OKYO PHARMA LTD (OKYO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- OKYO PHARMA LTD (OKYO) Insider and Institutional Ownership to learn about the owners and their transactions.
- OKYO PHARMA LTD (OKYO) Stock Chart to make your own analysis
- OKYO PHARMA LTD (OKYO) Latest news and press-releases to stay up to date.
Does OKYO PHARMA LTD (OKYO) stock pay dividends?
OKYO does not pay a dividend.
What is the Price/Earnings (PE) ratio of OKYO PHARMA LTD (OKYO)?
OKYO PHARMA LTD (OKYO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.19).
What is the Short Interest ratio of OKYO PHARMA LTD (OKYO) stock?
The outstanding short interest for OKYO PHARMA LTD (OKYO) is 1.16% of its float. Check the ownership tab for more information on the OKYO short interest.
OKYO Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to OKYO. When comparing the yearly performance of all stocks, OKYO is one of the better performing stocks in the market, outperforming 96.01% of all stocks.
OKYO Financial Highlights
Over the last trailing twelve months OKYO reported a non-GAAP Earnings per Share(EPS) of -1.19. The EPS increased by 3.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -594.77% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
OKYO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to OKYO. The Buy consensus is the average rating of analysts ratings from 7 analysts.